Pliant Therapeutics has been granted a patent for compounds that act as aVß6 integrin inhibitors, useful in treating fibrotic diseases like idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. The method involves administering the compound to individuals in need of treatment. GlobalData’s report on Pliant Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pliant Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Pliant Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Pliant Therapeutics's grant share as of February 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of fibrotic diseases using avß6 integrin inhibitors

Source: United States Patent and Trademark Office (USPTO). Credit: Pliant Therapeutics Inc

A recently granted patent (Publication Number: US11858931B2) discloses a method for treating fibrotic diseases by administering a specific compound to individuals in need. The compound, represented by formula (A), is effective in treating various fibrotic diseases such as pulmonary fibrosis, liver fibrosis, skin fibrosis, cardiac fibrosis, kidney fibrosis, gastrointestinal fibrosis, primary sclerosing cholangitis, and biliary fibrosis. Additionally, the method involves inhibiting aVß6 integrin and TGFß activation in cells by administering the compound or its pharmaceutically acceptable salt.

Furthermore, the patent claims encompass methods for modulating integrins in subjects, particularly aV subunit integrins, to treat fibrotic diseases like idiopathic pulmonary fibrosis, nonalcoholic fatty liver disease, diabetic nephropathy, and Crohn's Disease. The method involves selectively inhibiting aVß1 integrin or aVß6 integrin, or both, in the subject to address the specific fibrotic condition. The patent also covers the administration of pharmaceutical compositions containing the compound and a carrier or excipient for effective treatment of fibrotic diseases in individuals in need.

To know more about GlobalData’s detailed insights on Pliant Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies